(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 October 2025 (30.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/224069 A1

(51) International Patent Classification:

C07D 471/04 (2006.01)	*C07C 55/22* (2006.01)
C07D 207/08 (2006.01)	*C07C 63/04* (2006.01)
C07D 309/06 (2006.01)	*C07C 323/58* (2006.01)
C07D 403/06 (2006.01)	*A61K 31/351* (2006.01)
C07D 407/08 (2006.01)	*A61K 31/4196* (2006.01)
C07C 55/02 (2006.01)	*A61K 31/4375* (2006.01)
C07C 55/07 (2006.01)	*A61P 3/10* (2006.01)
C07C 55/08 (2006.01)	*A61P 13/12* (2006.01)

(21) International Application Number:
PCT/EP2025/060873

(22) International Filing Date:
22 April 2025 (22.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24171931.9 23 April 2024 (23.04.2024) EP

(71) Applicant: **BAYER AKTIENGESELLSCHAFT** [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE).

(72) Inventors: **BÄRFACKER, Lars**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **KOLKHOF, Peter**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **SCHIROK, Hartmut**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **BENET, Joan**; c/o ENANTIA, Baldiri Reixac 10, 08028 Barcelona Barcelona (ES). **TESSON, Nicolas**; c/o ENANTIA, Baldiri Reixac 10, 08028 Barcelona Barcelona (ES).

(74) Agent: **BIP PATENTS ASSOCIATION NO. 461**; c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50, 40789 Monheim am Rhein (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: CO-CRYSTALS OF FINERENONE, PECAVAPTAN, AND SGLT2 INHIBITORS

(57) Abstract: The invention refers to a co-crystal according to any one of formulae (I), (II), (III), (IV), (V), (VI) and/or (VII). Furthermore, the invention refers to a pharmaceutical formulation comprising any one of co-crystals according to formulae (I), (II), (III), (IV), (V), (VI) and/or (VII), the medical use of these co-crystals or the pharmaceutical formulation comprising such co-crystal(s) as well as to a process for preparing these co- crystals. The invention further refers to crystalline forms of and/or Empagliflozin as well as pharmaceutical comprising such crystalline forms.

WO 2025/224069 A1